Carlos Grijalva, M.D., M.P.H.

Associate Professor
Health Policy

Global Health Topic(s): Epidemiology, Vaccines

Research Interests: Vaccine Preventable Diseases, Influenza, Pneumonia, Pneumococcal Diseases 

Country(ies): Peru


Dr. Grijalva is an Associate Professor in the Division of Pharmacoepidemiology, Department of Health Policy, and Co-Director of the Vanderbilt’s Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) research center. Dr. Grijalva is also, a member of the Vanderbilt Epidemiology Center, a Scholar at the Vanderbilt Center for Health Services Research, and an investigator at the Veterans Affairs Tennessee Valley Geriatric Research Education and Clinical Center. His interests include the evaluation of medications’ safety and effectiveness; the design of observational studies; and, methodologies for comparative effectiveness research.

Dr. Grijalva is experienced designing and conducting studies of medications effects using large databases, and his research focuses on the assessments of medications used for diabetes, opioid analgesics, biologic medications, vaccine-preventable respiratory diseases - especially pneumococcal and influenza infections - and the evaluation of the effectiveness of vaccination and other preventive programs.

Dr. Grijalva is also the Principal Investigator for a prospective cohort study that was recently conducted among Peruvian Andean children to evaluate the burden of viral respiratory infections and the interaction between respiratory viruses and bacteria. He is also the Principal Investigator for a prospective cohort study of influenza transmission within households in Nashville, TN. Dr. Grijalva is also the project lead for a new Vanderbilt Trans-Institutional Program (TIPs), focused on the study of antimicrobial resistance. Dr. Grijalva also serves as the Course Director for Epidemiology I in the Vanderbilt Master of Public Health program, Course Director for PLAN in the School of Medicine, and as Program Director for the new Vanderbilt PROgRESS post-doctoral (T32) training program. He has published more than 160 peer-reviewed articles and mentored several junior investigators. His current work is supported by the National Institutes of Health, the Agency for Healthcare Research and Quality, the Food and Drug Administration and the Centers for Disease Control and Prevention, among other sources.


M.D., Universidad Nacional San Luis Gonzaga
M.P.H., Vanderbilt University